Abstract
Although there have been dramatic improvements in the treatment of children with non-hodgkin lymphoma, hodgkin lymphoma and histiocytic disorders over the past 3 decades, many still relapse or are refractory to primary therapy. In addition, late effects such as 2nd malignancies, cardiomyopathy and infertility remain a major concern. Thus, this review focuses on the current state of the science and, in particular, novel treatment strategies that are aimed at improving outcomes for all pediatric patients with lymphoma and histiocytic disorders while reducing treatment related morbidity.
| Original language | English |
|---|---|
| Pages (from-to) | 139-165 |
| Number of pages | 27 |
| Journal | Pediatric Clinics of North America |
| Volume | 62 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2015 |
Keywords
- Anaplastic large cell lymphoma (ALCL)
- Burkitt lymphoma (BL)
- Diffuse large B-cell lymphoma (DLBCL)
- Hodgkin lymphoma (HL)
- Juvenile xanthoganuloma (JXG)
- Langerhans cell histiocytosis (LCH)
- Posttransplant lymphoproliferative disease (PTLD)
- Rosai-Dorfman disease (RDD)
Fingerprint
Dive into the research topics of 'Pediatric lymphomas and histiocytic disorders of childhood'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver